| Autor: |
Natsumi Mizuno, Yoshiki Yanagawa |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
European Journal of Pharmacology. 915:174564 |
| ISSN: |
0014-2999 |
| DOI: |
10.1016/j.ejphar.2021.174564 |
| Popis: |
Tofacitinib is the first selective Janus kinase (JAK) 1/3 inhibitor approved for the treatment of rheumatoid arthritis and has been demonstrated to exhibit its efficacy through suppression of lymphocyte activation. Although macrophages are critically involved in the pathogenesis of rheumatoid arthritis, little is known about the influence of tofacitinib on macrophage activation especially expression of major histocompatibility complex class II (MHC II) and co-stimulatory molecule CD86. In the present study, we examined the effect of tofacitinib on the expression of MHC II and CD86 in RAW264.7 murine macrophages. Interferon (IFN)-γ induces the cell surface expression of MHC II and CD86. The treatment of tofacitinib at 0.5 μM significantly upregulated IFN-γ-induced expression of MHC II, while decreased the expression of CD86. Hence the population of CD86 |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect